By Tony Fong

NEW YORK (GenomeWeb News) – A Brooklyn, NY-based epigenetics firm has developed a method for identifying a potentially critical DNA nucleotide that only recently was discovered to be in humans and may play a vital role in switching genes on and off and in the development of diseases such as cancer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.

Sep
17
Sponsored by
Omicia

This online seminar will provide examples of how commercial and hospital-affiliated clinical labs are successfully developing and deploying high-throughput next-generation sequencing-based testing services for genetic diseases. 

Oct
07
Sponsored by
Personal Genome Diagnostics

This webinar will highlight the key considerations and applications of next-generation sequencing for managing non-small cell lung cancer patients using plasma-based approaches.